US · Healthcare · Biotechnology
EPS came in at -1.97 against a street estimate of -1.97 — a beat of 0.0%.
Analysts rate Moderna Inc a hold (6 buy, 17 hold, 4 sell out of 27) with an average price target of $119.56.
CONFIDENT Moderna beat Q2 revenue guidance despite seasonal weakness, cut cash costs 10% YoY, and reaffirmed 10% full-year growth. mNEXSPIKE captured 34% of 65+ COVID vaccine market. Flu vaccine nearing FDA approval; Intismeran Phase III melanoma interim expected H2 2026. Q2 2026 International strength from long-term partnerships offsetting U.S. vaccine rate headwinds. Europe unaccessible until 2026 due to pandemic-era exclusivity; seen as major growth lever afterward. Analysts pressed Intismeran event accrual timeline, Phase III statistical bar vs Phase II, and norovirus case accrual rate. Management declined to disclose study powering but emphasized Phase II durability and translational mechanism data as confidence drivers; acknowledged norovirus case shortage was seasonal/strain-driven, not enrollment-driven. 2026-07-31…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 11.44% |
| BlackRock Inc | 7.42% |
| Vanguard Capital Management, LLC | 5.73% |
| Capital World Investors | 5.58% |
| Baillie Gifford & Co Limited. | 4.56% |
| Vanguard Portfolio Management, LLC | 3.91% |
| State Street Corp | 3.72% |
| Geode Capital Management, LLC | 2.36% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 MODERNA, INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • Moderna completed a private offering of $3,000,000,000 in 0.00% Convertible Senior Notes due 2 | 2026-09-01 |
| Quarterly report · Q2 2026 MODERNA, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Product Sales (6M 2026): $446 million vs. $200 million (6M 2025) – increase of 123% • To | 2026-07-31 |
| Results announced · Q3 2026 MODERNA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $145 million (vs. $142 million in Q2 2025) – comprised of $94 million | 2026-07-31 |
| Board / officer change · Q3 2026 MODERNA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this filing • Document is a corporate governance announcement d | 2026-07-08 |
| Charter / bylaws change · Q2 2026 MODERNA, INC. - FORM 8-K SUMMARY (May 6, 2026) HEADLINE NUMBERS • Annual Meeting Date: May 6, 2026 • Total Votes Cast for Director Sandra Horning: 2 | 2026-05-11 |
| Quarterly report · Q1 2026 MODERNA, INC. - Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Net Product Sales Q1 2026: $352 million (vs. $86 million in Q1 2025) – 309% increase ye | 2026-05-01 |
| Proxy statement · Q2 2026 MODERNA, INC. PROXY SUMMARY FOR RETAIL INVESTORS --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class II directors (Sandra Horning, M. | 2026-03-16 |
| Annual report FY2025 MODERNA, INC. – 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Total revenue 2025: $1.9 billion (largely from COVID vaccine sales) • Market capitaliz | 2026-02-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Moderna Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.